Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

Autor: Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno

Publikováno v: Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-12 (2024)

Abstract Background No randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients with a broad spectrum of cardiovascular risk. We reporte

Externí odkaz: https://doaj.org/article/a409dae7b8d64bffbc67fb3a8cee406b

Coronary Flow Reserve, Inflammation, and Myocardial Strain

Autor: Viviany R. Taqueti, Amil M. Shah, Brendan M. Everett, Aruna D. Pradhan, Gregory Piazza, Courtney Bibbo, Jon Hainer, Victoria Morgan, Ana Carolina do A. H. de Souza, Hicham Skali, Ron Blankstein, Sharmila Dorbala, Samuel Z. Goldhaber, Michel R. Le May, Benjamin J.W. Chow, Robert A. deKemp, Fadi G. Hage, Rob S. Beanlands, Peter Libby, Robert J. Glynn, Scott D. Solomon, Paul M. Ridker, Marcelo F. Di Carli

Publikováno v: JACC: Basic to Translational Science. 8:141-151

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1b8f9fcb5b6d958c5b8603e6b6f6f254
https://doi.org/10.1016/j.jacbts.2022.08.009

Canakinumab's Effect Against Subsequent Gout Flares and High‐Sensitivity C‐Reactive Protein Levels: A Causal Mediation Analysis

Autor: Kazuki Yoshida, Robert J. Glynn, Hyon K. Choi, Brendan M. Everett, Yi Li, Jean G. MacFadyen, Paul M. Ridker, Daniel H. Solomon

Publikováno v: Arthritis Care & Research. 75:817-824

The objective of this study was to quantify the value of early suppression of high-sensitivity C-reactive protein (hsCRP) levels as a biomarker of the protective role of canakinumab against future gout flares.We conducted a post hoc causal mediation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35b42b4a54a5f6433023ead55e00a83c
https://doi.org/10.1002/acr.24832

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Autor: Aruna, Das Pradhan, Robert J, Glynn, Jean-Charles, Fruchart, Jean G, MacFadyen, Elaine S, Zaharris, Brendan M, Everett, Stuart E, Campbell, Ryu, Oshima, Pierre, Amarenco, Dirk J, Blom, Eliot A, Brinton, Robert H, Eckel, Marshall B, Elam, João S, Felicio, Henry N, Ginsberg, Assen, Goudev, Shun, Ishibashi, Jacob, Joseph, Tatsuhiko, Kodama, Wolfgang, Koenig, Lawrence A, Leiter, Alberto J, Lorenzatti, Boris, Mankovsky, Nikolaus, Marx, Børge G, Nordestgaard, Dénes, Páll, Kausik K, Ray, Raul D, Santos, Handrean, Soran, Andrey, Susekov, Michal, Tendera, Koutaro, Yokote, Nina P, Paynter, Julie E, Buring, Peter, Libby, Paul M, Ridker, Maureen, McClelland

Publikováno v: Das Pradhan, A, Glynn, R J, Fruchart, J C, MacFadyen, J G, Zaharris, E S, Everett, B M, Campbell, S E, Oshima, R, Amarenco, P, Blom, D J, Brinton, E A, Eckel, R H, Elam, M B, Felicio, J S, Ginsberg, H N, Goudev, A, Ishibashi, S, Joseph, J, Kodama, T, Koenig, W, Leiter, L A, Lorenzatti, A J, Mankovsky, B, Marx, N, Nordestgaard, B G, Páll, D, Ray, K K, Santos, R D, Soran, H, Susekov, A, Tendera, M, Yokote, K, Paynter, N P, Buring, J E, Libby, P & Ridker, P M 2022, ' Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. ', New England Journal of Medicine, vol. 387, no. 21, pp. 1923-1934 . https://doi.org/10.1056/NEJMoa2210645

Background High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these levels would lower the incidence of cardiovascular events is uncertain. Pemafibrate, a selective peroxisome proliferator-activated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73f084970bad344fb37812ba1fc7407c
https://pubmed.ncbi.nlm.nih.gov/36342123

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics

Autor: Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Seoyoung C. Kim, Mehdi Najafzadeh, Lisette Koeneman, Soulmaz Fazeli Farsani, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno

Publikováno v: JAMA network open. 5(10)

ImportanceLimited evidence is available on the comparative effectiveness of empagliflozin vs alternative second-line glucose-lowering agents in patients with type 2 diabetes (T2D) receiving routine care who have a broad spectrum of cardiorenal risk.O

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3c384e1a6685ef507ee2b6ced9db540
https://pubmed.ncbi.nlm.nih.gov/36264574